Clinical trial
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee
NCT00477217 · Novartis, Industry · Withdrawn
Key facts
| NCT number | NCT00477217 |
|---|---|
| Title | Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee |
| Official title | A Randomized, Double-blind, Placebo-controlled, Proof of Concept Study of Zoledronic Acid in Spontaneous Osteonecrosis of the Knee (SONK) |
| Lead sponsor | Novartis, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteonecrosis |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 0 |
| Start date | Jan 1, 2008 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | May 23, 2007 |
| Last update posted | Sep 23, 2016 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: